May 20, 2021Open Access

Anticoagulant Therapy for Cancer-Associated Venous Thromboembolism after Cancer Remission

NHNobuhiro HaraCounseling Center TLTetsumin LeeMusashino Red Cross Hospital KMKentaro MitsuiNational Cerebral and Cardiovascular Center

Key Result

Anticoagulant therapy outcomes for patients with cancer-associated venous thromboembolism were investigated during active cancer and after remission.

Structured PICO

Does completing anticoagulant therapy improve outcomes compared to continuing it in patients with cancer-associated VTE after cancer remission?

Population

338 patients with cancer-associated venous thromboembolism (VTE) who received anticoagulant therapy, divided into a cancer remission group (n=112) and a continued cancer treatment group (n=226). The remission group was further divided into completion of anticoagulation (n=89) and continued anticoagulation (n=23).

Intervention

Completion (discontinuation) of anticoagulant therapy (warfarin or direct oral anticoagulants) after cancer remission.

Comparator

Continued anticoagulant therapy after cancer remission.

Outcome

Composite of all-cause death, VTE recurrence, and bleeding events at 1-year follow-up.composite

Discontinuing anticoagulant therapy after cancer remission in patients with cancer-associated VTE is associated with high event-free survival and low recurrence rates, suggesting it is safe and reduces bleeding risk compared to continuing therapy.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Objectives: To examine the outcomes of anticoagulant therapy for patients with venous thromboembolism (VTE) with active cancer and the outcomes after cancer remission with and without anticoagulant therapy.

Ask AI

Helpful

Bookmark

View Full Paper